Press release
CGRP Inhibitor Market Sees Major Uptake Across Hospitals Pharmacies and Specialty Clinics Globally
CGRP Inhibitor Market
According to the latest research by InsightAce Analytic, the CGRP Inhibitor Market is valued at USD 3.3 Bn in 2024, and it is expected to reach USD 8.5 Bn by the year 2034, with a CAGR of 10.2% during the forecast period of 2025-2034.
Global CGRP Inhibitor Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2984
Calcitonin Gene-Related Peptide (CGRP) inhibitors represent a novel class of therapeutics primarily developed for the prevention and treatment of migraine headaches. CGRP, a neuropeptide involved in pain transmission and cerebral vasodilation, plays a critical role in the underlying pathophysiology of migraines. CGRP inhibitors function by targeting either the peptide itself or its receptor, thereby reducing the frequency, severity, and duration of migraine episodes.
Migraines are not only associated with intense physical discomfort but also contribute to substantial economic burdens due to lost productivity and absenteeism. The development of CGRP inhibitors reflects significant investments in research and development by leading pharmaceutical companies. These therapies have demonstrated strong clinical efficacy and represent a promising advancement in the management of migraine disorders, addressing a key unmet need in neurological care.
List of Prominent Players in the CGRP Inhibitor Market:
• Eli Lilly and Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• AbbVie Inc.
• Amgen Inc
• Novartis AG
• Allergan
• Biohaven Pharmaceutical Holding Company Ltd.
• Sun Pharmaceutical Industries Ltd
• Lundbeck
• AstraZeneca plc
• F. HoffmannLa Roche Ltd
• BristolMyers Squibb Company
• Other Market Players
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics
Drivers:
The global rise in the prevalence of complex migraines and severe headache disorders is a key factor driving the demand for Calcitonin Gene-Related Peptide (CGRP) inhibitors. Migraines, often accompanied by sensory hypersensitivity, nausea, and vomiting, represent a growing public health concern due to their debilitating nature. Recognizing the substantial unmet medical need and the associated market potential, pharmaceutical companies are intensifying research and development efforts to formulate innovative CGRP inhibitor therapies.
Challenges:
Despite their clinical effectiveness, the high cost of CGRP inhibitors remains a significant challenge, particularly in low- and middle-income countries, where affordability and access are limited. The financial burden on patients and healthcare systems can hinder widespread adoption. Additionally, the potential for resistance to CGRP inhibitors may impact their long-term efficacy, necessitating the development of alternative treatment strategies. Addressing these challenges is essential for sustaining market growth and ensuring broader patient access to these advanced therapeutic options.
Regional Trends:
North America is expected to dominate the CGRP inhibitor market in terms of revenue share, with a strong projected compound annual growth rate (CAGR) in the coming years. This growth is attributed to the region's advanced healthcare infrastructure, significant investment in research and development, and the presence of key pharmaceutical companies and research institutions. The high prevalence of migraine-related disorders in the region further underscores the demand for effective treatments, thereby reinforcing North America's position as a leading market for CGRP inhibitors.
Recent Developments:
• In March 2023, Pfizer Inc. announced that the U.S. FDA has approved ZAVZPRET (zavegepant), the inaugural and exclusive calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute management of migraine, with or without aura, in adults. In its crucial Phase 3 trial, ZAVZPRET demonstrated statistical superiority over placebo regarding the co-primary goals of pain relief and alleviation of the most bothersome symptom at two hours post-administration. The crucial study also exhibited pain alleviation as soon as 15 minutes in a predetermined secondary goal compared to placebo.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2984
Segmentation of CGRP Inhibitor Market-
By Treatment-
• Preventive
• Acute
By Route of Administration-
• Oral
• Nasal
• Intravenous
By End-User-
• Hospitals
• Pharmacies
• Specialty Clinics
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/cgrp-inhibitor-market/2984
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CGRP Inhibitor Market Sees Major Uptake Across Hospitals Pharmacies and Specialty Clinics Globally here
News-ID: 4071516 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
GMP Cell Therapy Consumables Market Growth and Restrain Factors Analysis Report …
InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global GMP Cell Therapy Consumables Market Size, Share & Trends Analysis Report By Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell…
High-End Synthetic Suede Market Study Analysis with Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global High-End Synthetic Suede Market Size, Share & Trends Analysis Report By Product (Woven And Non-Woven) And Application (Automotive, Fashion, Furniture And Other Applications (Including Residential And Commercial))- Market Outlook And Industry Analysis 2031"
The High-End Synthetic Suede Market is estimated to reach over USD 2.06 billion by exhibiting a CAGR of 5.75% during the…
Gluten Free Snacks Market
"Green Fertilizer Market" in terms of revenue was estimated to be worth $2.2 billion in 2024 and is poised to reach $ 4.1 Billion by 2034, growing at a CAGR of 6.5% from 2025 to 2034 according to a new report by InsightAce Analytic.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1570
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global green fertilizer Market are:
• Technology development
• Shifting tastes of consumers
• Higher…
Gluten Free Snacks Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gluten Free Snacks Market Size, Share & Trends Analysis Report By Product Type (Nutrition Bars, Candy Bars, Salty Snacks, Nuts), Distributional Channel (Convenience Stores, Supermarket And Hypermarket, Specialty Stores, Drugstores And Pharmacies, E Commerce) And Generation (Millennials, Generation X And Baby Boomers)- Market Outlook And Industry Analysis 2034"
The global gluten free snacks market is estimated…
More Releases for CGRP
Mycophenolate Mofetil Market is Projected to Expand Steady Growth in Forecast Ye …
The global Mycophenolate Mofetil market size is projected to grow from 2021 to 2026. The demand for Mycophenolate Mofetil can be attributed to patient benefits, growth of the manufacturing sector, increasing production and growing capacity in healthcare industry, and healthy growth of pharmaceutical and food & beverage industry in developing countries, are supporting the growth of the Mycophenolate Mofetil market.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/242255 .
Pandemic impact…
Covid-19 Impact on Albendazole API Market 2021: Growth by Top Company - TEVA, Sh …
Global Albendazole API Market Synopsis:
The exclusive research report on the Global Albendazole API Market 2021-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Albendazole API Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.
According to the market research study, Albendazole is a medication used for…
Wearable wireless Patch Device Market 18% CGRP to 2023: Global Market Analysis, …
A wearable wireless healthcare patch is an all-in-one monitor that can measure heart rate, breathing patterns and other vital signs, offering both clinical and consumer healthcare uses.
The Wearable wireless Patch Device Market to grow at a CAGR of +18% during the Forecast period. Wearable Medical Devices have grown phenomenally over the years in terms of their usage.
Request Sample Copy of this report:
http://qyreports.com/request-sample?report-id=101421
Top Key Vendors:
Fitbit, Garmin, Jawbone, Lifewatch, Misfit, Monica…
Global Migraine Market 2018 Key Players: Eli Lilly & Company, Teva Pharmaceutica …
Migraine Market:
WiseGuyReports.com adds “Migraine Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024” reports to its database.
Executive Summary
FDA has recently approved first ever novel migraine preventive drug that resorts to prevention rather than treatment. It is posed as a breakthrough drug with immense market potential in upcoming years. The report “Global Migraine Market (By Nations-The US, the UK, Germany, France, Italy, Spain and Japan; Drugs- Triptan, CGRP,…
In-Depth Analysis of Calcitonin Gene Related Peptide (CGRP) Pipeline and Therape …
Market Research Hub (MRH) has included a new extensive and fact-based research publication, titled "Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2018" in its extensive research database. This study examines comprehensive information on the therapeutics under development for Calcitonin Gene Related Peptide, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Moreover, its pipeline analysis by companies…
Global Market Report on Calcitonin Gene Related Peptide (CGRP)-Pipeline Review, …
"The Report Calcitonin Gene Related Peptide (CGRP)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Calcitonin Gene Related Peptide (CGRP)-Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of…
